Chemotherapy plus concurrent irreversible electroporation improved local tumor control in unresectable hilar cholangiocarcinoma compared with chemotherapy alone

References

• Nath MC, Torbenson MS, Erickson LA. Perihilar cholangiocarcinoma. Mayo Clin Proc. 2018;93(3):397–398.
   PubMed Web of Science ®Google Scholar
• Chen P, Li B, Zhu Y, et al. Establishment and validation of a prognostic nomogram for patients with resectable perihilar cholangiocarcinoma. Oncotarget. 2016;7(24):37319–37330.
   PubMedGoogle Scholar
• Vibert E, Boleslawski E. Transplantation versus resection for hilar cholangiocarcinoma: an argument for shifting treatment paradigms for resectable disease. Ann Surg. 2019;269(1):e5–e6.
   PubMed Web of Science ®Google Scholar
• Groot Koerkamp B, Wiggers JK, Gonen M, et al. Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram. Ann Oncol. 2016;27(4):753.
   PubMed Web of Science ®Google Scholar
• Matsuo K, Rocha FG, Ito K, et al. The blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg. 2012;215(3):343–355.
   PubMed Web of Science ®Google Scholar
• Lunsford KE, Javle M, Heyne K, Methodist–MD Anderson Joint Cholangiocarcinoma Collaborative Committee (MMAJCCC), et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol. 2018;3(5):337–348.
   PubMed Web of Science ®Google Scholar
• Watanabe A, Kida M, Miyazawa S, et al. Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer. World J Gastroenterol. 2015;21(19):5979–5984.
   PubMed Web of Science ®Google Scholar
• Uwagawa T, Sakamoto T, Abe K, et al. Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer. Cancer Chemother Pharmacol. 2015;75(1):191–196.
   PubMed Web of Science ®Google Scholar
• Shoji H, Morizane C, Sakamoto Y, et al. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer. Jpn J Clin Oncol. 2016;46(2):132–137.
   PubMed Web of Science ®Google Scholar
• Morizane C, Okusaka T, Mizusawa J, members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG), et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019;30(12):1950–1958.
   PubMed Web of Science ®Google Scholar
• Tsukiyama I, Ejiri M, Yamamoto Y, et al. A Cost-Effectiveness analysis of gemcitabine plus cisplatin versus gemcitabine alone for treatment of advanced biliary tract cancer in Japan. J Gastrointest Cancer. 2017;48(4):326–332.
   PubMed Web of Science ®Google Scholar
• Wagner A, Denzer UW, Neureiter D, et al. Temoporfin improves efficacy of photodynamic therapy in advanced biliary tract carcinoma: a multicenter prospective phase II study. Hepatology. 2015;62(5):1456–1465.
   PubMed Web of Science ®Google Scholar
• Dolak W, Schreiber F, Schwaighofer H, Austrian Biliary RFA Study Group, et al. Endoscopic radiofrequency ablation for malignant biliary obstruction: a nationwide retrospective study of 84 consecutive applications. Surg Endosc. 2014;28(3):854–860.
   PubMed Web of Science ®Google Scholar
• Laquiere A, Boustiere C, Leblanc S, et al. Safety and feasibility of endoscopic biliary radiofrequency ablation treatment of extrahepatic cholangiocarcinoma. Surg Endosc. 2016;30(3):1242–1248.
   PubMed Web of Science ®Google Scholar
• Mahadevan A, Dagoglu N, Mancias J, et al. Stereotactic body radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma. J Cancer. 2015;6(11):1099–1104.
   PubMed Web of Science ®Google Scholar
• Chen R, Lu F, Wu F, et al. An analytical solution for temperature distributions in hepatic radiofrequency ablation incorporating the heat-sink effect of large vessels. Phys Med Biol. 2018;63(23):235026
   PubMed Web of Science ®Google Scholar
• Kodama H, Ueshima E, Gao S, et al. High power microwave ablation of normal swine lung: impact of duration of energy delivery on adverse event and heat sink effects. Int J Hyperthermia. 2018;34(8):1186–1193.
   PubMed Web of Science ®Google Scholar
• Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality-clinical implications. Technol Cancer Res Treat. 2007;6(1):37–48.
   PubMed Web of Science ®Google Scholar
• Martin EK, Neal B, Egger ME, et al. Safety and efficacy of irreversible electroporation in the treatment of obstructive jaundice in advanced hilar cholangiocarcinoma. Hpb (Oxford). 2018;20(11):1092–1097.
   PubMed Web of Science ®Google Scholar
• Li M, Li K, Qi X, et al. Percutaneous transhepatic biliary stent implantation for obstructive jaundice of perihilar cholangiocarcinoma: a prospective study on predictors of stent patency and survival in 92 patients. J Vasc Interv Radiol. 2016;27(7):1047–1055e2.
   PubMed Web of Science ®Google Scholar
• Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234(4):507–517.
   PubMed Web of Science ®Google Scholar
• Appelbaum L, Ben-David E, Faroja M, et al. Irreversible electroporation ablation: creation of large-volume ablation zones in in vivo porcine liver with four-electrode arrays. Radiology. 2014;270(2):416–424.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Palmer DH, Wasan HS, Advanced Biliary Cancer Working Group, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690–701.
   PubMed Web of Science ®Google Scholar
• Cardella JF, Kundu S, Miller DL, Society of Interventional Radiology, et al. Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol. 2009;20(7 Suppl):S189–S91.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Technology Assessment Committee of the Society of Interventional Radiology Image Image-guided tumor ablation: standardization of terminology and reporting criteria-a 10-year update: supplement to the consensus document. J Vasc Interv Radiol. 2014;25(11):1706–1708.
   PubMed Web of Science ®Google Scholar
• Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol. 2010;33(1):11–17.
   PubMed Web of Science ®Google Scholar
• Esnaola NF, Meyer JE, Karachristos A, et al. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer. 2016;122(9):1349–1369.
   PubMed Web of Science ®Google Scholar
• Bhutiani N, Agle S, Li Y, et al. Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinoma. J Surg Oncol. 2016;114(2):181–186.
   PubMed Web of Science ®Google Scholar
• Belfiore MP, Reginelli A, Maggialetti N, et al. Preliminary results in unresectable cholangiocarcinoma treated by CT percutaneous irreversible electroporation: feasibility, safety and efficacy. Med Oncol. 2020;37(5):45.
   PubMed Web of Science ®Google Scholar
• Shady W, Petre EN, Do KG, et al. Percutaneous microwave versus radiofrequency ablation of colorectal liver metastases: ablation with clear margins (A0) provides the best local tumor control. J Vasc Interv Radiol. 2018;29(2):268–275e1.
   PubMed Web of Science ®Google Scholar
• Niessen C, Thumann S, Beyer L, et al. Percutaneous irreversible electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors. Sci Rep. 2017;7:43687.
   PubMed Web of Science ®Google Scholar
• Mansour JC, Aloia TA, Crane CH, et al. Hilar cholangiocarcinoma: expert consensus statement. HPB. 2015;17(8):691–699.
   PubMed Web of Science ®Google Scholar
• Ghafoori AP, Nelson JW, Willett CG, et al. Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2011;81(3):654–659.
   PubMed Web of Science ®Google Scholar